NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT
Post# of 175
(Total Views: 196)
Posted On: 09/28/2022 3:57:15 PM
NetworkNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Technology Enabling 12-Lead ECG Receives Patent from USPTO
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been granted a patent from the United States Patent and Trademark Office (“USPTO”). The patent covers proprietary technology that allows the HeartBeam AIMIGo(TM) credit card-sized device to enable a 12-lead ECG anytime or anywhere. According to the announcement, the innovative tech and AIMIGo device makes it possible for a patient to record signals outside of a medical setting with a diagnostic synthesized 12-lead ECG that is immediately transmitted to a physician for review and diagnosis; the now-patented HeartBeam technology is designed to assist the physician in quickly and accurately identify a heart attack, or myocardial infarction. “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care. This could reduce the critical time to intervention for heart attack patients, saving lives and reducing healthcare costs by ruling out a heart attack and reducing the number of emergency room visits.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been granted a patent from the United States Patent and Trademark Office (“USPTO”). The patent covers proprietary technology that allows the HeartBeam AIMIGo(TM) credit card-sized device to enable a 12-lead ECG anytime or anywhere. According to the announcement, the innovative tech and AIMIGo device makes it possible for a patient to record signals outside of a medical setting with a diagnostic synthesized 12-lead ECG that is immediately transmitted to a physician for review and diagnosis; the now-patented HeartBeam technology is designed to assist the physician in quickly and accurately identify a heart attack, or myocardial infarction. “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care. This could reduce the critical time to intervention for heart attack patients, saving lives and reducing healthcare costs by ruling out a heart attack and reducing the number of emergency room visits.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)